Skip to main content

Table 1 Clinical features of patients with circulating tumor cells

From: Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

  No CTC (n = 39) CTC (n = 34) P value Estimate (95% CI)
Age at primary diagnosis, years, mean (SD) 58.38 (11.85) 55.1 (11.04) 0.444 − 2.76 (− 8.49, 2.84)
Age at first CTC evaluation, years, mean (SD) 63.53 (11.69) 59.58 (10.7) 0.163 − 4.11 (− 9.27, 1.63)
Stage at diagnosis, n (%)    0.679
 I 4 (10.53%) 5 (14.71%)   
 IA 1 (2.63%) 0 (0%)   
 II 5 (13.16%) 4 (11.76%)   
 IIA 1 (2.63%) 4 (11.76%)   
 III 11 (28.95%) 7 (20.59%)   
 IIIA 2 (5.26%) 0 (0%)   
 IIIC 0 (0%) 2 (5.88%)   
 IV 14 (36.84%) 11 (32.35%)   
Lymphocyte node involvement, n (%)    0.881
 N0 11 (31.43%) 8 (25.81%)   
 N1 11 (31.43%) 14 (45.16%)   
 N2 6 (17.14%) 0 (0%)   
 N3 6 (17.14%) 9 (29.03%)   
Histologic subtype, n (%)    0.964
 Invasive lobular 6 (15.38%) 4 (11.76%)   
 Invasive ductal 31 (79.49%) 29 (85.29%)   
 Inflammatory invasive lobular 1 (2.56%) 1 (2.94%)   
 Inflammatory 2 (5.13%) 2 (5.88%)   
% of ER+ cells, mean (SD) 65.82 (42.48) 59.79 (40.93) 0.386 0 (− 10, 0)
% of PR+ cells, mean (SD) 38.97 (40.04) 26.35 (33.78) 0.171 − 4 (− 20, 0)
% of Ki-67+ cells, mean (SD) 27.08 (17.13) 31.59 (21.55) 0.514 5 (− 5, 10)
HER2+ 7 (17.95%) 7 (22.58%) 0.766 1.33 (0.35–5.11)
Triple-negative 4 (10.81%) 3 (9.68%) 1.000 0.89 (0.12–5.73)
Tumor grade    0.985
 1 4 (10.53%) 4 (12.12%)   
 2 17 (44.74%) 14 (42.42%)   
 3 17 (44.74%) 15 (45.45%)   
Bisphosphonates 9 (23.68%) 7 (20.59%) 0.784 0.84 (0.23–2.94)
Denosumab 16 (41.03%) 5 (14.71%) 0.019 0.25 (0.06–0.86)
Radiotherapy 22 (56.41%) 13 (38.24%) 0.160 0.48 (0.17–1.35)
Relapse
 Any 31 (79.49%) 25 (73.53%) 0.589 0.72 (0.21–2.45)
 Local 3 (7.69%) 4 (11.76%) 0.698 1.59 (0.25–11.72)
 Metastasis 26 (66.67%) 19 (55.88%) 0.470 0.64 (0.22–1.82)
Days between primary diagnosis and relapse, mean (SD) 1954.08 (2042.25) 1893.48 (1853.86) 0.966 − 9.37 (− 1000, 756)
Established metastatic disease at CTC evaluation 35 (89.74%) 30 (88.24%) 1.000 0.86 (0.15–5.04)
Number of metastatic sites, mean (SD) 2.09 (1.01) 1.9 (0.94) 0.473 0 (− 1, 0)
Metastasis site, n (%)
 Bone 27 (69.23%) 17 (51.52%) 0.150 0.45 (0.15–1.28)
 Liver 10 (25.64%) 12 (36.36%) 0.447 1.57 (0.51–4.9)
 Lymph node 9 (23.08%) 10 (30.3%) 0.599 1.38 (0.43–4.54)
 Pleural 7 (17.95%) 2 (6.06%) 0.162 0.29 (0.03–1.68)
 Peritoneal 3 (7.69%) 4 (12.12%) 0.698 1.59 (0.25–11.72)
 Lung 4 (10.26%) 4 (12.12%) 1.000 1.16 (0.2–6.83)
 Skin 3 (7.69%) 0 (0%) 0.243 0 (0–2.74)
 Brain 2 (5.13%) 2 (6.06%) 1.000 1.15 (0.08–16.76)
 Uterus 1 (2.56%) 1 (3.03%) 1.000 1.15 (0.01–92.67)
 Muscular 1 (2.56%) 2 (6.06%) 0.595 2.35 (0.12–143.61)
  1. Abbreviations: ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, PR Progesterone receptor
  2. The table shows clinical features of patients with and without circulating tumor cells (CTCs)